Ask AI
ProCE Banner Activity

Multiple Receptor TKIs in Recurrent GBM in the Absence of Actionable Targets

Slideset
In this downloadable slideset, Manmeet S. Ahluwalia, MD, FACP, highlights regorafenib in the REGOMA trial and other multiple receptor kinase inhibitors for patients with GBM.

Released: November 22, 2019

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bayer Healthcare Pharma

Faculty Disclosure

Primary Author

Manmeet S. Ahluwalia, MD, MBA, FASCO

Fernandez Family Endowed Chair in Cancer Research
Chief of Medical Oncology
Chief Scientific Officer & Deputy Director
Herbert Wertheim Cancer Institute
Baptist Health South Florida
Professor, Herbert Wertheim College of Medicine
Florida International University
Miami, Florida